A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

Inclusion Criteria

• •Asian participants aged 18 years or older at screening.
• •Participants with minimum 1 year history of migraine (with or without aura) prior to the Screening Visit, consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
• •1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
• •2. Migraine attacks, on average, lasting about 4-72 hours if untreated.
• •3. Not more than 8 attacks of moderate or severe pain intensity per month within last 3 months.
• •4. Participants must be able to distinguish migraine attacks from tension/cluster headaches.
• •5. At least 2 consistent migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and throughout the Screening Phase (participant self-report).
• •6. Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Phase (participant self-report).
• •7. Participants on prophylactic migraine medication are permitted to remain on therapy if they have been on a stable dose for at least 3 months prior to Screening Visit, and if the dose is not expected to change through the End of Treatment Visit.
• •8. Participants with contraindications for use of triptans may be included provided they meet all other study entry criteria.